Irbesartan in Type 2 Diabetes With Microalbuminuria 2 - IRMA 2

Description:

The Irbesartan in Type 2 Diabetes With Microalbuminuria 2 (IRMA 2) was a prospective, randomized, placebo-controlled, multicenter study designed to evaluate the renoprotective effect of the angiotensin-II-receptor antagonist irbesartan in hypertensive patients with type 2 diabetes and microalbuminuria.